Thank you to all who attended WuXi Night in Boston! The WuXi Boston office along with WuXi’s International Discovery Service Unit (IDSU), Lab Testing Division (LTD), Chemistry Services Unit (CSU), our process development and manufacturing subsidiary STA, LabNetwork, and WuXi Healthcare Ventures II, were happy to host this event for colleagues and peers across specializations and industries to come together and celebrate innovation and collaboration […]
About WuXi AppTec
This author has yet to write their bio.Meanwhile lets just say that we are proud WuXi AppTec contributed a whooping 42 entries.
Entries by WuXi AppTec
WuXi presents a Q&A with Dr. Osvaldo (Lalo) Flores, CSO of Novira Therapeutics, a leading biotech based in Philadelphia, PA with novel approaches in anti-HBV drug discovery. Hepatitis B infection presents a significant unmet medical need. An estimated 350 million people worldwide are living with chronic HBV infection and many of these infected patients incur a higher […]
An Interview with the New Head of IDSU: Dr. Steve Yang, Executive Vice President and Chief Operating Officer of WuXi AppTec WuXi’s EVP & COO Steve Yang was recently appointed as the new head of WuXi’s International Discovery Services Unit (IDSU). He brings with him years of industry experience and expertise. This summer, Steve has […]
Meet Dr. John Wai, PhD Vice President of Medicinal Chemistry Prior to WuXi, John spent over 20 years at Merck Research Laboratories, contributing to the discovery efforts of many programs, from target validation & lead identification to lead optimization & early development. This includes HIV-1 non-nucleoside reverse transcriptase inhibitors, ras-farnesyl protein transferase inhibitors, fibrinogen […]
Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead. Josune Orb et. al. Journal of Medicinal Chemistry, 2015, 58(5), pp.2678-2702. Development of Orthogonally Protected Hypusine for Solid-Phase Peptide Synthesis. Aimin Song et. al. The Journal of Organic Chemistry, 2015, 80(7). Discovery of a Series […]
Medicinal Chemistry Emerging Formats for Next-Generation Antibody Drug Conjugates. Mahendra P. Deonarain et. al. Expert Opinion on Drug Discovery, 2015, 10 (5) pp. 463-481. Identification of Small-Molecule Inhibitors of Calcineurin-NFATc Signaling That Mimic the PxIxIT Motif of Calcineurin Binding Partners. Minos-Timotheos Matsoukas et. al. Science Signal. 2015, 8(382), pp. ra63. Pharmacological Repression of PPARγ […]
Date: Nov 14, 2014 This WuXi AppTec event is complementary and open to life science professionals globally. Nearly 500 life science innovators tuned in to our global webinar on November 14th to gain insights into the unique challenges and opportunities in rare disease R&D. We brought together our industry’s foremost experts from Third Rock Ventures, […]
Breakthrough therapies are changing the market for new medicines targeting life-threatening diseases, and redefining R&D strategies from small biotech to large pharmaceutical companies. With the promise to drastically shorten drug development timelines, breakthrough designation (BTD) affords advantages including expedited FDA review, flexibility in IND requirements, and options for smaller clinical trials. In this complimentary live webinar open to life science professional globally, WuXi brings together industry experts to discuss their discovery stories, lessons learned that led to the coveted status of BTD, and their perspectives on how BTD is redefining the R&D landscape.
Alzheimer’s, schizophrenia and other central nervous system disorders are some of the biggest unmet medical needs facing healthcare today with enormous burden to society. Aging populations are set to further increase the need for safe and effective drugs.
We are honored to have received the “Excellent Partner Award” from the Lilly China Research and Development Center (LCRDC) in March 2014.